Chimerix Q2 EPS $(0.21) Beats $(0.24) Estimate, Sales $26.00K Miss $230.00K Estimate; Capital Available to Fund Operations Is $233M
Portfolio Pulse from Benzinga Newsdesk
Chimerix (NASDAQ:CMRX) reported Q2 losses of $(0.21) per share, beating the analyst consensus estimate of $(0.23) by 8.7%. However, the company's quarterly sales of $26.00K missed the analyst consensus estimate of $640.00K by 95.94%. The company has $233M available to fund operations.
August 04, 2023 | 12:55 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Chimerix's Q2 EPS beat estimates but sales significantly missed estimates. The company has $233M available for operations.
Chimerix's Q2 earnings per share beat estimates, which is positive for the stock. However, the company's sales missed estimates by a significant margin, which is a negative signal. The availability of $233M for operations provides some financial stability, but the sales miss could negatively impact the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100